Immunological monitoring strategies for cytomegalovirus infection. Immune-based therapies;Estrategias de monitorización inmunológica para la infección por citomegalovirus. Tratamientos de base inmunológica

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 29, Issue SUPPL.6, 2011, Pages 28-32

  Bohórquez, Sara Cantisán ^a   Ortega, David Navarro ^b,c  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Active CMV infection; Adoptive T lymphocyte transfer; Cellular immunity; Cytomegalovirus; T lymphocyte quantification; Vaccination

Indexed keywords

CYTOMEGALOVIRUS VACCINE; PEPTIDE; VIRUS ANTIGEN;

ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FLOW CYTOMETRY; IMMUNOLOGICAL MONITORING; ORGAN TRANSPLANTATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RISK; SOLID ORGAN TRANSPLANTATION; T LYMPHOCYTE; VIRUS REPLICATION;

CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOTHERAPY; MONITORING, IMMUNOLOGIC; T-LYMPHOCYTES;

EID: 84860439427     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(11)70054-4     Document Type: Article

References (72)

1. P. Moss, and N. Khan CD8(+) T-cell immunity to cytomegalovirus Hum Immunol 65 2004 456 464
2. R. Vescovini, C. Biasini, F.F. Fagnoni, A.R. Telera, L. Zanlari, and M. Pedrazzoni Massive load of functional effector CD4+ and CD8+ T cells against cytomegalovirus in very old subjects J Immunol 179 2007 4283 4291
3. R. Elkington, S. Walker, T. Crough, M. Menzies, J. Tellam, and M. Bharadwaj Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers J Virol 77 2003 5226 5240
4. A.W. Sylwester, B.L. Mitchell, J.B. Edgar, C. Taormina, C. Pelte, and F. Ruchti Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects J Exp Med 202 2005 673 685
5. S. Cantisán, J. Torre-Cisneros, R. Lara, A. Rodríguez- Benot, F. Santos, and J. Gutiérrez-Aroca Age-dependent association between low frequency of CD27/CD28 expression on pp65 CD8+ T cells and cytomegalovirus replication after transplantation Clin Vaccine Immunol 16 2009 1429 1438
6. E. Derhovanessian, A. Larbi, and G. Pawelec Biomarkers of human immunosenescence: Impact of Cytomegalovirus infection Curr Opin Immunol 21 2009 440 445
7. L. Couzi, X. Lafarge, V. Pitard, M. Neau-Cransac, C. Dromer, and M.A. Billes Gammadelta T cell expansion is closely associated with cytomegalovirus infection in all solid organ transplant recipients Transpl Int 24 2011 e40 e42
8. J. Dechanet, P. Merville, F. Berge, G. Bone-Mane, J.L. Taupin, and P. Michel Major expansion of gammadelta T lymphocytes following cytomegalovirus infection in kidney allograft recipients J Infect Dis 179 1999 1 8
9. X. Lafarge, P. Merville, M.C. Cazin, F. Berge, L. Potaux, and J.F. Moreau Cytomegalovirus infection in transplant recipients resolves when circulating gammadelta T lymphocytes expand, suggesting a protective antiviral role J Infect Dis 184 2001 533 541
10. T. Crough, and R. Khanna Immunobiology of human cytomegalovirus: From bench to bedside Clin Microbiol Rev 22 2009 76 98
11. M.K. Gandhi, and R. Khanna Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments Lancet Infect Dis 4 2004 725 738
12. S. Kijpittayarit, A.J. Eid, R.A. Brown, C.V. Paya, and R.R. Razonable Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation Clin Infect Dis 44 2007 1315 1320
13. K. Hadaya, C. De Rham, C. Bandelier, S. Ferrari-Lacraz, S. Jendly, and T. Berney Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation Am J Transplant 8 2008 2674 2683
14. M. Stern, H. Elsasser, G. Honger, J. Steiger, S. Schaub, and C. Hess The number of activating KIR genes inversely correlates with the rate of CMV infection/reactivation in kidney transplant recipients Am J Transplant 8 2008 1312 1317
15. T.W. Kuijpers, P.A. Baars, C. Dantin, M. Van den Burg, R.A. Van Lier, and E. Roosnek Human NK cells can control CMV infection in the absence of T cells Blood 112 2008 914 915
16. D. Navarro, P. Paz, S. Tugizov, K. Topp, J. La Vail, and L. Pereira Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells Virology 197 1993 143 158
17. J.F. Navarro, and C. Mora-Fernández Antibody level after hepatitis B vaccination Nephrol Dial Transplant 12 1997 2207
18. L. Pereira, E. Lennette, P. Paz, and D. Navarro Humoral immunity to glycoprotein B in primary and recurrent cytomegalovirus infection Progress in Cytomegalovirus Research 1993 Elsevier Science Publishers Amsterdam 145 148
19. J. Alberola, A. Tamarit, R. Igual, and D. Navarro Early neutralizing and glycoprotein B (gB)-specific antibody responses to human cytomegalovirus (HCMV) in immunocompetent individuals with distinct clinical presentations of primary HCMV infection J Clin Virol 16 2000 113 122
20. D. Di Martino, M.P. Terranova, A. Valetto, L. Scarso, M. Faraci, and E. Lanino An unusual pattern of B-cell immunological reconstitution after allogeneic stem cell transplantation: A possible correlation with CMV reactivation? Pediatr Transplant 13 2008 1050 1052
21. I. Muñoz, A. Gutiérrez, C. Gimeno, A. Farga, J. Alberola, and C. Solano Lack of association between the kinetics of human cytomegalovirus (HCMV) glycoprotein B (gB)-specific and neutralizing serum antibodies and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant J Med Virol 65 2001 77 84
22. D.R. Snydman, B.G. Werner, B. Heinze-Lacey, V.P. Berardi, N.L. Tilney, and R.L. Kirkman Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients N Engl J Med 317 1987 1049 1054
23. M.E. Falagas, D.R. Snydman, R. Ruthazer, J. Griffith, B.G. Werner, and R. Freeman Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group Clin Transplant 11 1997 432 437
24. N.S. Goldfarb, R.K. Avery, M. Goormastic, A.C. Mehta, R. Schilz, and N. Smedira Hypogammaglobulinemia in lung transplant recipients Transplantation 71 2001 242 246
25. S. Doron, R. Ruthazer, B.G. Werner, A. Rabson, and D.R. Snydman Hypogammaglobulinemia in liver transplant recipients: Incidence, timing, risk factors, and outcomes Transplantation 81 2006 697 703
26. A. Humar, C. Paya, M.D. Pescovitz, E. Domínguez, K. Washburn, and E. Blumberg Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients Am J Transplant 4 2004 644 649
27. A. Humar, T. Mazzulli, G. Moussa, R.R. Razonable, C.V. Paya, and M.D. Pescovitz Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R-transplant recipients Am J Transplant 5 2005 1065 1070
28. G. Gerna, E. Percivalle, D. Lilleri, L. Lozza, C. Fornara, and G. Hahn Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells J Gen Virol 86 2005 275 284
29. G. Gerna, A. Sarasini, M. Patrone, E. Percivalle, L. Fiorina, and G. Campanini Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection J Gen Virol 89 2008 853 865
30. S. Giulieri, and O. Manuel QuantiFERON(R)-CMV assay for the assessment of cytomegalovirus cell-mediated immunity Expert Rev Mol Diagn 11 2011 17 25
31. D. Kumar, S. Chernenko, G. Moussa, I. Cobos, O. Manuel, and J. Preiksaitis Cellmediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients Am J Transplant 9 2009 1214 1222
32. S. Walker, C. Fazou, T. Crough, R. Holdsworth, P. Kiely, and M. Veale Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV Transpl Infect Dis 9 2007 165 170
33. G.P. Westall, N.A. Mifsud, and T. Kotsimbos Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity Am J Transplant 8 2008 1749 1754
34. J. Torre-Cisneros Toward the individualization of cytomegalovirus control after solid-organ transplantation: The importance of the "individual pathogenic balance" Clin Infect Dis 49 2009 1167 1168
35. C. Solano, I. Benet, M.A. Clari, J. Nieto, R. De la Cámara, and J. López Enumeration of cytomegalovirus-specific interferongamma CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection Haematologica 93 2008 1434 1436
36. C. Solano, and D. Navarro Clinical virology of cytomegalovirus infection following hematopoietic transplantation Future Virology 5 2010 1 14
37. N. Tormo, C. Solano, I. Benet, M.A. Clari, J. Nieto, and R. De la Cámara Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients Bone Marrow Transplant 45 2009 543 549
38. T. Bunde, A. Kirchner, B. Hoffmeister, D. Habedank, R. Hetzer, and G. Cherepnev Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells J Exp Med 201 2005 1031 1036
39. T. Crough, C. Fazou, J. Weiss, S. Campbell, M.P. Davenport, and S.C. Bell Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8(+) T-cell response J Virol 81 2007 11538 11542
40. L.E. Gamadia, E.B. Remmerswaal, J.F. Weel, F. Bemelman, R.A. Van Lier, and I.J. Ten Berge Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease Blood 101 2003 2686 2692
41. G. Gerna, D. Lilleri, C. Fornara, G. Comolli, L. Lozza, and C. Campana Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation Am J Transplant 6 2006 2356 2364
42. D. Lilleri, P. Zelini, C. Fornara, G. Comolli, and G. Gerna Inconsistent responses of cytomegalovirus-specific T cells to pp65 and IE-1 versus infected dendritic cells in organ transplant recipients Am J Transplant 7 2007 1997 2005
43. F.M. Mattes, A. Vargas, J. Kopycinski, E.G. Hainsworth, P. Sweny, and G. Nebbia Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation Am J Transplant 8 2008 990 999
44. G. Nebbia, F.M. Mattes, C. Smith, E. Hainsworth, J. Kopycinski, and A. Burroughs Polyfunctional cytomegalovirus-specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation Am J Transplant 8 2008 2590 2599
45. R. Radha, S. Jordan, D. Puliyanda, S. Bunnapradist, A. Petrosyan, and N. Amet Cellular immune responses to cytomegalovirus in renal transplant recipients Am J Transplant 5 2005 110 117
46. M. Sester, U. Sester, B.C. Gartner, M. Girndt, A. Meyerhans, and H. Kohler Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection J Am Soc Nephrol 13 2002 2577 2584
47. U. Sester, B.C. Gartner, H. Wilkens, B. Schwaab, R. Wossner, and I. Kindermann Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation Am J Transplant 5 2005 1483 1489
48. O.A. Shlobin, E.E. West, N. Lechtzin, S.M. Miller, M. Borja, and J.B. Orens Persistent cytomegalovirus-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients J Immunol 176 2006 2625 2634
49. A. Krishnan, W. Zhou, S.F. Lacey, A.P. Limaye, D.J. Diamond, and C. La Rosa Programmed death-1 receptor and interleukin-10 in liver transplant recipients at high risk for late cytomegalovirus disease Transpl Infect Dis 12 2010 363 370
50. C. La Rosa, A. Krishnan, J. Longmate, J. Martínez, P. Manchanda, and S.F. Lacey Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease J Infect Dis 197 2008 25 33
51. T.W. Hoffmann, J.M. Halimi, M. Buchler, F. Velge-Roussel, A. Goudeau, and A. Al-Najjar Association between a polymorphism in the human programmed death-1 (PD-1) gene and cytomegalovirus infection after kidney transplantation J Med Genet 47 2009 54 58
52. H. Einsele, E. Roosnek, N. Rufer, C. Sinzger, S. Riegler, and J. Loffler Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy Blood 99 2002 3916 3922
53. L. Dong, Z.Y. Gao, L.J. Chang, Y. Liang, X.Y. Tan, and J.H. Liu Adoptive transfer of cytomegalovirus/Epstein-Barr virus-specific immune effector cells for therapeutic and preventive/preemptive treatment of pediatric allogeneic cell transplant recipients J Pediatr Hematol Oncol 32 2010 e31 e37
54. H. Einsele, M. Kapp, and G.U. Grigoleit CMV-specific T cell therapy Blood Cells Mol Dis 40 2008 71 75
55. K.P. Micklethwaite, L. Clancy, U. Sandher, A.M. Hansen, E. Blyth, and V. Antonenas Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation Blood 112 2008 3974 3981
56. B. Horn, L. Bao, K. Dunham, M. Stamer, S. Adler, and M. Cowan Infusion of cytomegalovirus specific cytotoxic T lymphocytes from a sero-negative donor can facilitate resolution of infection and immune reconstitution Pediatr Infect Dis J 28 2009 65 67
57. G.R. Hill, S.K. Tey, L. Beagley, T. Crough, J.A. Morton, and A.D. Clouston Successful immunotherapy of HCMV disease using virus-specific T cells expanded from an allogeneic stem cell transplant recipient Am J Transplant 10 2009 173 179
58. P. Scheinberg, J.J. Melenhorst, J.M. Brenchley, B.J. Hill, N.F. Hensel, and P.K. Chattopadhyay The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor Blood 114 2009 5071 5080
59. G. Brestrich, S. Zwinger, A. Fischer, M. Schmuck, A. Rohmhild, and M.H. Hammer Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy Am J Transplant 9 2009 1679 1684
60. M.R. Schleiss Prospects for development and potential impact of a vaccine against congenital cytomegalovirus (CMV) infection J Pediatr 151 2007 564 570
61. S.P. Adler Immunoprophylaxis against cytomegalovirus disease Scand J Infect Dis Suppl 99 1995 105 109
62. S.A. Plotkin, M.L. Smiley, H.M. Friedman, S.E. Starr, G.R. Fleisher, and C. Wlodaver Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants Lancet 1 1984 528 530
63. S.P. Adler, S.A. Plotkin, E. Gonczol, M. Cadoz, C. Meric, and J.B. Wang A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne) J Infect Dis 180 1999 843 846
64. K. Berencsi, Z. Gyulai, E. Gonczol, S. Pincus, W.I. Cox, and S. Michelson A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects J Infect Dis 183 2001 1171 1179
65. D.I. Bernstein, M.R. Schleiss, K. Berencsi, E. Gonczol, M. Dickey, and P. Khoury Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults J Infect Dis 185 2002 686 690
66. R.F. Pass, A.M. Duliege, S. Boppana, R. Sekulovich, S. Percell, and W. Britt A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant J Infect Dis 180 1999 970 975
67. R.F. Pass, C. Zhang, A. Evans, T. Simpson, W. Andrews, and M.L. Huang Vaccine prevention of maternal cytomegalovirus infection N Engl J Med 360 2009 1191 1199
68. E.A. Reap, J. Morris, S.A. Dryga, M. Maughan, T. Talarico, and R.E. Esch Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus Vaccine 25 2007 7441 7449
69. M.R. Schleiss, J.C. Lacayo, Y. Belkaid, A. McGregor, G. Stroup, and J. Rayner Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection J Infect Dis 195 2007 789 798
70. J. Zhong, M. Rist, L. Cooper, C. Smith, and R. Khanna Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus PLoS One 3 2008 e3256
71. M.R. Schleiss VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection Curr Opin Mol Ther 11 2009 572 578
72. M.K. Wloch, L.R. Smith, S. Boutsaboualoy, L. Reyes, C. Han, and J. Kehler Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects J Infect Dis 197 2008 1634 1642